Permeability Analysis of Neuroactive Drugs Through a Dynamic Microfluidic In Vitro Blood–Brain Barrier Model

Annals of Biomedical Engineering

Volumn 42, Issue 12, 2014, Pages 2379-2391

  Booth, R ^a   Kim, H ^a  

^a Department of Electrical and Computer Engineering   (United States)

Author keywords

BBB; Central nervous system; Drug discovery; Endothelial cells; Microsystems; BBB

Indexed keywords

BLOOD; DRUG PRODUCTS; DYNAMIC MODELS; MECHANICAL PERMEABILITY; MICROFLUIDICS; MICROSYSTEMS; SHEAR STRESS;

BARRIER MODEL; CENTRAL NERVOUS SYSTEMS; DRUG DISCOVERY; DRUG PERMEABILITIES; ELECTRICAL RESISTANCES; LINEAR CORRELATION; PERMEABILITY ANALYSIS; STATIC AND DYNAMIC MODELS;

ENDOTHELIAL CELLS;

2-(5,7-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-3-YLAMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE; 4 AMINOBUTYRIC ACID; AMINE; BENZAZEPINE DERIVATIVE; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; ETHOSUXIMIDE; GABAPENTIN; INDOLE DERIVATIVE; LACTATE DEHYDROGENASE; PIPERIDINE DERIVATIVE; PYRROLE DERIVATIVE; QUINOXALINE DERIVATIVE; SERTRALINE; SUNITINIB; TETRALIN DERIVATIVE; TRAXOPRODIL; VALINE; VARENICLINE;

ANALOGS AND DERIVATIVES; ANIMAL; BLOOD BRAIN BARRIER; CELL CULTURE; CELL SURVIVAL; COCULTURE; DRUG EFFECTS; ENDOTHELIUM CELL; GLIA; METABOLISM; MICROFLUIDIC ANALYSIS; MOUSE; PERMEABILITY; RAT; SPRAGUE DAWLEY RAT; TRANSPORT AT THE CELLULAR LEVEL;

AMINES; ANIMALS; BENZAZEPINES; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CELL SURVIVAL; CELLS, CULTURED; COCULTURE TECHNIQUES; CYCLOHEXANECARBOXYLIC ACIDS; ENDOTHELIAL CELLS; ETHOSUXIMIDE; GAMMA-AMINOBUTYRIC ACID; INDOLES; L-LACTATE DEHYDROGENASE; MICE; MICROFLUIDIC ANALYTICAL TECHNIQUES; NEUROGLIA; PERMEABILITY; PIPERIDINES; PYRROLES; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; SERTRALINE; TETRAHYDRONAPHTHALENES; VALINE;

EID: 84919415828     PISSN: 00906964     EISSN: 15739686     Source Type: Journal    
DOI: 10.1007/s10439-014-1086-5     Document Type: Article

References (54)

1. Abbott, N. J. Prediction of blood–brain barrier permeation in drug discovery from in vivo, in vitro and in silico models. Drug Discov. Today Technol. 1:407–416, 2004.
2. Achyuta, A. K. H., A. J. Conway, R. B. Crouse, E. C. Bannister, R. N. Lee, C. P. Katnik, A. A. Behensky, J. Cuevas, and S. S. Sundaram. A modular approach to create a neurovascular unit-on-a-chip. Lab Chip. 13:542–553, 2013.
3. Adams, C. P., and V. V. Brantner. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff. (Millwood). 25:420–428, 2006.
4. Aran, K., L. A. Sasso, N. Kamdar, and J. D. Zahn. Irreversible, direct bonding of nanoporous polymer membranes to PDMS or glass microdevices. Lab Chip. 10:548–552, 2010.
5. Booth, R., and H. Kim. Characterization of a microfluidic in vitro model of the blood–brain barrier (μbbb). Lab Chip. 12:1784–1792, 2012.
6. Booth, R., S. Noh, and H. Kim. A multiple-channel, multiple-assay platform for characterization of full-range shear stress effects on vascular endothelial cells. Lab Chip. 14(11):1880–1890, 2014.
7. Bynum, J. Unpublished Tabulations Based on Data from the Medicare Current Beneficiary Survey for 2008. Nov 2011, Dartmouth Medical School
8. Cecchelli, R., V. Berezowski, S. Lundquist, M. Culot, M. Renftel, M. P. Dehouck, and L. Fenart. Modelling of the blood–brain barrier in drug discovery and development. Nat. Rev. Drug Discov. 6:650–661, 2007.
9. Chien, S. Molecular basis of rheological modulation of endothelial functions: importance of stress direction. Biorheology 43:95–116, 2006.
10. Chien, S., S. Li, and Y. J. Shyy. Effects of mechanical forces on signal transduction and gene expression in endothelial cells. Hypertension 31:162–169, 1998.
11. Chueh, B. H., D. Huh, C. R. Kyrtsos, T. Houssin, N. Futai, and S. Takayama. Leakage-free bonding of porous membranes into layered microfluidic array systems. Anal. Chem. 79:3504–3508, 2007.
12. Couchman, L., M. Birch, R. Ireland, A. Corrigan, S. Wickramasinghe, D. Josephs, J. Spicer, and R. Flanagan. An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography–tandem mass spectrometry. Anal. Bioanal. Chem. 403:1685–1695, 2012.
13. Crivori, P., G. Cruciani, P.-A. Carrupt, and B. Testa. Predicting blood–brain barrier permeation from three-dimensional molecular structure. J. Med. Chem. 43:2204–2216, 2000.
14. Cucullo, L., M. S. McAllister, K. Kight, L. Krizanac-Bengez, M. Marroni, M. R. Mayberg, K. A. Stanness, and D. Janigro. A new dynamic in vitro model for the multidimensional study of astrocyte–endothelial cell interactions at the blood–brain barrier. Brain Res. 951:243–254, 2002.
15. Cucullo, L., M. Hossain, V. Puvenna, N. Marchi, and D. Janigro. The role of shear stress in blood–brain barrier endothelial physiology. BMC Neurosci. 12:40, 2011.
16. De Boer, A., I. Van Der Sandt, and P. Gaillard. The role of drug transporters at the blood–brain barrier. Ann. Rev. Pharmacol. Toxicol. 43:629–656, 2003.
17. Deak, K., K. Takacs-Novak, K. Tihanyi, and B. Noszal. Physico-chemical profiling of antidepressive sertraline: solubility, ionisation, lipophilicity. Med. Chem. 2:385–389, 2006.
18. Desai, S. Y., M. Marroni, L. Cucullo, L. Krizanac-Bengez, M. R. Mayberg, M. T. Hossain, G. G. Grant, and D. Janigro. Mechanisms of endothelial survival under shear stress. Endothelium 9:89–102, 2002.
19. Ferri, C. P., M. Prince, C. Brayne, H. Brodaty, L. Fratiglioni, M. Ganguli, K. Hall, K. Hasegawa, H. Hendrie, and Y. Huang. Global prevalence of dementia: a delphi consensus study. Lancet 366:2112–2117, 2006.
20. Galan-Valiente, J., R. Soto-Otero, and G. Sierra-Marcuño. Simultaneous measurement of ethosuximide and phenobarbital in brain tissue, serum and urine by HPLC. Biomed. Chromatogr. 3:49–52, 1989.
21. Gloor, S. M., M. Wachtel, M. F. Bolliger, H. Ishihara, R. Landmann, and K. Frei. Molecular and cellular permeability control at the blood–brain barrier. Brain Res. Rev. 36:258–264, 2001.
22. Griep, L., F. Wolbers, B. de Wagenaar, P. Ter Braak, B. Weksler, I. A. Romero, P. Couraud, I. Vermes, A. van der Meer, and A. van den Berg. BBB on chip: microfluidic platform to mechanically and biochemically modulate blood–brain barrier function. Biomed. Microdevices 15:145–150, 2013.
23. Hebert, L. E., L. A. Beckett, P. A. Scherr, and D. A. Evans. Annual incidence of alzheimer disease in the united states projected to the years 2000 through 2050. Alzheimer Dis. Assoc. Disord. 15:169–173, 2001.
24. Henderson, J., R. D. Ricker, B. A. Bidlingmeyer, and C. Woodward. Rapid, accurate, sensitive, and reproducible HPLC analysis of amino acids. Amino Acid Anal. Zorbax Eclipse AAA Columns Agilent. 1100:1–10, 2000.
25. Jain, D. S., M. Sanyal, G. Subbaiah, U. Pande, and P. Shrivastav. Rapid and sensitive method for the determination of sertraline in human plasma using liquid chromatography–tandem mass spectrometry (LC–MS/MS). J. Chromatogr. B 829:69–74, 2005.
26. Johnson, K., A. Shah, S. Jaw-Tsai, J. Baxter, and C. Prakash. Metabolism, pharmacokinetics, and excretion of a highly selectiven-methyl-d-aspartate receptor antagonist, traxoprodil, in human cytochrome p450 2d6 extensive and poor metabolizers. Drug Metab. Dispos. 31:76–87, 2003.
27. Kola, I., and J. Landis. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3:711–716, 2004.
28. Kushnir, M. M., J. Crossett, P. I. Brown, and F. M. Urry. Analysis of gabapentin in serum and plasma by solid-phase extraction and gas chromatography-mass spectrometry for therapeutic drug monitoring. J. Anal. Toxicol. 23:1–6, 1999.
29. Li, G., M. J. Simon, L. M. Cancel, Z. D. Shi, X. Ji, J. M. Tarbell, B. Morrison, 3rd, and B. M. Fu. Permeability of endothelial and astrocyte cocultures: in vitro blood–brain barrier models for drug delivery studies. Ann. Biomed. Eng. 38:2499–2511, 2010.
30. Nakagawa, S., M. A. Deli, H. Kawaguchi, T. Shimizudani, T. Shimono, A. Kittel, K. Tanaka, and M. Niwa. A new blood–brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem. Int. 54:253–263, 2009.
31. Neuhaus, W., R. Lauer, S. Oelzant, U. P. Fringeli, G. F. Ecker, and C. R. Noe. A novel flow based hollow-fiber blood–brain barrier in vitro model with immortalised cell line pbmec/c1-2. J. Biotechnol. 125:127–141, 2006.
32. Neuhaus, W., V. E. Plattner, M. Wirth, B. Germann, B. Lachmann, F. Gabor, and C. R. Noe. Validation of in vitro cell culture models of the blood–brain barrier: tightness characterization of two promising cell lines. J. Pharm. Sci. 97:5158–5175, 2008.
33. Obach, R. S., A. E. Reed-Hagen, S. S. Krueger, B. J. Obach, T. N. O’Connell, K. S. Zandi, S. Miller, and J. W. Coe. Metabolism and disposition of varenicline, a selective α4β2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab. Disposit. 34:121–130, 2006.
34. Oberoi, R. K., R. K. Mittapalli, J. Fisher, and W. F. Elmquist. Sunitinib LC-MS/MS assay in mouse plasma and brain tissue: application in CNS distribution studies. Chromatographia 76:1657–1665, 2013.
35. Omidi, Y., L. Campbell, J. Barar, D. Connell, S. Akhtar, and M. Gumbleton. Evaluation of the immortalised mouse brain capillary endothelial cell line, b.End3, as an in vitro blood–brain barrier model for drug uptake and transport studies. Brain Res. 990:95–112, 2003.
36. Pangalos, M. N., L. E. Schechter, and O. Hurko. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat. Rev. Drug Discov. 6:521–532, 2007.
37. Pardridge, W. M. The blood–brain barrier: bottleneck in brain drug development. NeuroRx. 2:3–14, 2005.
38. Pardridge, W. M., W. H. Oldendorf, P. Cancilla, and H. J. Frank. Blood–brain barrier: interface between internal medicine and the brain. Annal. Intern. Med. 105:82–95, 1986.
39. Pardridge, W. M., D. Triguero, J. Yang, and P. A. Cancilla. Comparison of in vitro and in vivo models of drug transcytosis through the blood–brain barrier. J. Pharmacol. Exp. Ther. 253:884–891, 1990.
40. Peeters, M., M. J. Gunthorpe, P. J. Strijbos, P. Goldsmith, N. Upton, and M. F. James. Effects of pan- and subtype-selective n-methyl-d-aspartate receptor antagonists on cortical spreading depression in the rat: therapeutic potential for migraine. J. Pharmacol. Exp. Ther. 321:564–572, 2007.
41. Polk, B. J., A. Stelzenmuller, G. Mijares, W. MacCrehan, and M. Gaitan. Ag/AgCl microelectrodes with improved stability for microfluidics. Sensors Actuators B 114:239–247, 2006.
42. Prabhakarpandian, B., M.-C. Shen, J. B. Nichols, I. R. Mills, M. Sidoryk-Wegrzynowicz, M. Aschner, and K. Pant. SyM-BBB: a microfluidic blood brain barrier model. Lab Chip. 13:1093–1101, 2013.
43. Reichel, A. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept. Chem. Biodivers. 6:2030–2049, 2009.
44. Rollema, H., A. Shrikhande, K. M. Ward, F. D. Tingley, 3rd, J. W. Coe, B. T. O’Neill, E. Tseng, E. Q. Wang, R. J. Mather, R. S. Hurst, K. E. Williams, M. de Vries, T. Cremers, S. Bertrand, and D. Bertrand. Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. Br. J. Pharmacol. 160:334–345, 2010.
45. Summerfield, S. G., A. J. Lucas, R. A. Porter, P. Jeffrey, R. N. Gunn, K. R. Read, A. J. Stevens, A. C. Metcalf, M. C. Osuna, P. J. Kilford, J. Passchier, and A. D. Ruffo. Toward an improved prediction of human in vivo brain penetration. Xenobiotica 38:1518–1535, 2008.
46. Tzima, E., M. Irani-Tehrani, W. B. Kiosses, E. Dejana, D. A. Schultz, B. Engelhardt, G. Cao, H. DeLisser, and M. A. Schwartz. A mechanosensory complex that mediates the endothelial cell response to fluid shear stress. Nature 437:426–431, 2005.
47. Vastag, M., and G. M. Keseru. Current in vitro and in silico models of blood–brain barrier penetration: a practical view. Curr. Opin. Drug Discov. Dev. 12:115–124, 2009.
48. Wang, Y., and D. F. Welty. The simultaneous estimation of the influx and efflux blood–brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach. Pharm. Res. 13:398–403, 1996.
49. Wolburg, H., S. Noell, A. Mack, K. Wolburg-Buchholz, and P. Fallier-Becker. Brain endothelial cells and the glio-vascular complex. Cell Tissue Res. 335:75–96, 2009.
50. Wood, K. M., T. A. Lanz, K. J. Coffman, S. L. Becker, J. van Deusen, C. E. Nolan, K. E. Richter, J. E. Finley, T. M. Brown, and M. A. Brodney. P2-375: efficacy of the novel γ-secretase inhibitor, Pf-3084014, in reducing aβ in brain, CSF, and plasma in guinea pigs and tg2576 mice. Alzheimer’s Dement. 4:T482–T483, 2008.
51. Yuan, W., G. Li, E. S. Gil, T. L. Lowe, and B. M. Fu. Effect of surface charge of immortalized mouse cerebral endothelial cell monolayer on transport of charged solutes. Ann. Biomed. Eng. 38:1463–1472, 2010.
52. Zehendner, C. M., H. J. Luhmann, and C. R. Kuhlmann. Studying the neurovascular unit: an improved blood–brain barrier model. J. Cereb. Blood Flow Metab. 29:1879–1884, 2009.
53. Zhang, Y., C. S. Li, Y. Ye, K. Johnson, J. Poe, S. Johnson, W. Bobrowski, R. Garrido, and C. Madhu. Porcine brain microvessel endothelial cells as an in vitro model to predict in vivo blood–brain barrier permeability. Drug Metab. Dispos. 34:1935–1943, 2006.
54. Zhang, L., H. Zhu, T. I. Oprea, A. Golbraikh, and A. Tropsha. Qsar modeling of the blood–brain barrier permeability for diverse organic compounds. Pharm. Res. 25:1902–1914, 2008.